Eli Lilly and Company Stock Price, News, Quote & History

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Eli Lilly and Company

Lilly to Acquire Adverum Biotechnologies

Lilly's Verzenio® prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment

Lilly confirms date and conference call for third-quarter 2025 financial results announcement

Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes

Lilly to present new clinical data for Verzenio and multiple novel pipeline programs at the 2025 European Society for Medical Oncology Annual Meeting

Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis

Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystem

Lilly's Kisunla receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease

U.S. FDA approves Inluriyo for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer

Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas

5 Small-cap Biotech ETFs to Watch in 2025

5 Biggest Pharma Stocks in 2025

Top 5 Small-cap Pharma Stocks of 2025

5 Biggest Pharmaceutical ETFs in 2025

5 US Longevity and Anti-aging Stocks to Watch in 2025

Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

Latest News

Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG

Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® in Adults with Moderate Atopic Dermatitis

Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025

Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025

Lion One Metals Engages Atrium Research Corporation

Latest News

Outlook Reports world

Featured Stocks

Browse Companies